14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BBIO vs BHVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over BridgeBio Pharma, Inc. (BBIO) on higher Unified Composite conviction (42.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while BBIO wins 3–2 across the 6-pillar growth and valuation breakdown. BBIO trades at $77.18 (N/M Forward P/E, -37.3% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While BBIO currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -37.3% operating margin) and revenue trajectory (+0.0% vs. +192.6% YoY).
Technical & Structure Timing Caution: BBIO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BBIO vs BHVN. Trailing 12-month operating profitability (BBIO -37.3% vs BHVN 0.0%) and valuation multiples (BBIO N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BBIO vs BHVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over BridgeBio Pharma, Inc. (BBIO) on higher Unified Composite conviction (42.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while BBIO wins 3–2 across the 6-pillar growth and valuation breakdown. BBIO trades at $77.18 (N/M Forward P/E, -37.3% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BBIO currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -37.3% operating margin) and revenue trajectory (+0.0% vs. +192.6% YoY). Technical & Structure Timing Caution: BBIO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BBIO leads the Growth & Scale pillar: BBIO posts +192.6% YoY revenue growth and +0.0% YoY earnings growth on $946M TTM revenue (94.3% gross margin, -37.3% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BBIO generates $946M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, BBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.
BBIO screens cheaper on headline valuation multiples. BBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.1x EV/Revenue (-39.1% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BBIO (-1789.7% ROE) versus BHVN (-799.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BBIO carries 44.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 1.68x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.88β · 38% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.